Investigational drug · Phase 3
Nuvastatic
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fatigue, Colon Cancer, Breast Neoplasms.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
6
Any phase or sponsor naming "Nuvastatic"
First trial start
2025
Jun 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Nuvastatic", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fatigue
- Colon Cancer
- Breast Neoplasms
- Quality of Life
- Chemotherapy, Adjuvant
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Nuvastatic" as an intervention, largest first.
Natureceuticals Sdn BhdIndustry
NCT07669454 · 250 participants (planned) · Start Oct 1, 2025 · Primary completion Oct 31, 2026
Drug: Nuvastatic 300; Placebo · For: Fatigue Related to Cancer Treatment; Colon Cancer
Sites: Visakhapatnam, India; Mysore, India; Jalgaon, India · 6 sites in all
- Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast CancerPivotal-lookingRecruiting
Natureceuticals Sdn BhdIndustry
NCT07669467 · 250 participants (planned) · Start Oct 1, 2025 · Primary completion Oct 30, 2026
Drug: Nuvastatic 300; Placebo · For: Fatigue Related to Cancer Treatment; Breast Cancer
Sites: Visakhapatnam, India; Mysore, India; Jalgaon, India · 6 sites in all
- Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line ChemotherapyPivotal-lookingRecruiting
Natureceuticals Sdn BhdIndustry
NCT07669519 · 180 participants (planned) · Start Aug 18, 2025 · Primary completion Mar 31, 2027
Drug: Nuvastatic™; Placebo · For: Fatigue; Colon Cancer
Sites: Srikakulam, India; Belagavi, India; Mysuru, India · 6 sites in all
- A Study to Evaluate the Efficacy and Safety of Orally Administered Extract of Orthosiphon Stamineus (NuvastaticTM-C5OSEW5050ESA) in Patient With Breast Cancer Undergoing ChemotherapyPivotal-lookingCompleted
Natureceuticals Sdn BhdIndustry
NCT07669506 · 180 participants · Start Jun 17, 2025 · Primary completion Apr 25, 2026
Drug: Nuvastatic ™; Placebo · For: Breast Neoplasms; Fatigue; Quality of Life and 1 more
Sites: Srikakulam, India; Belagavi, India; Mysuru, India · 7 sites in all
- Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.Pivotal-lookingCompleted
Natureceuticals Sdn BhdIndustry
NCT04552600 · 100 participants · Start Sep 1, 2019 · Primary completion Aug 10, 2022
Drug: Nuvastatic · For: Diabetic Retinopathy
Sites: Pune, India
- To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.Status unknown
Natureceuticals Sdn BhdIndustry
NCT04542447 · 10 participants (planned) · Start Sep 1, 2020 · Primary completion Sep 30, 2020
Drug: Nuvastatic · For: Covid19
Sites: Ghaziabad, India
Newest research
PubMed records naming it or its code names, newest first.
- A phase II randomized, double-blind, placebo-controlled study of Nuvastatic (C50SEW505OESA), a standardized rosmarinic acid-rich polymolecular botanical extract formulation to reduce cancer-related fatigue in patients with solid tumors.
Ng ML, Majid AMSA, Yee SM, et al. · Support Care Cancer 2024
- Polymolecular botanical drug of Orthosiphon stamineus extract (C5OSEW5050ESA) as a complementary therapy to overcome gemcitabine resistance in pancreatic cancer cells.
Yehya AHS, Asif M, Abdul Majid AMS, et al. · J Tradit Complement Med 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.